109 related articles for article (PubMed ID: 18808444)
1. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis.
Buckland A; Bodger K
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1287-96. PubMed ID: 18808444
[TBL] [Abstract][Full Text] [Related]
2. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
Brereton N; Bodger K; Kamm MA; Hodgkins P; Yan S; Akehurst R
J Med Econ; 2010 Mar; 13(1):148-61. PubMed ID: 20141380
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM
BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262
[TBL] [Abstract][Full Text] [Related]
5. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
Irvine EJ; Yeh CH; Ramsey D; Stirling AL; Higgins PD
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1278-86. PubMed ID: 18808446
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial.
Connolly MP; Nielsen SK; Currie CJ; Marteau P; Probert CS; Travis SP
J Crohns Colitis; 2009 Sep; 3(3):168-74. PubMed ID: 21172266
[TBL] [Abstract][Full Text] [Related]
7. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
[TBL] [Abstract][Full Text] [Related]
8. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
9. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
10. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain].
Gisbert JP; Gomollón F; Méndez I
Gastroenterol Hepatol; 2016 Mar; 39(3):199-212. PubMed ID: 26072136
[TBL] [Abstract][Full Text] [Related]
12. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.
Connolly MP; Boersma C; Oldenburg B
Neth J Med; 2012 Aug; 70(6):272-7. PubMed ID: 22859419
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
Park KT; Perez F; Tsai R; Honkanen A; Bass D; Garber A
J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):489-96. PubMed ID: 21694634
[TBL] [Abstract][Full Text] [Related]
14. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
17. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
Connolly MP; Poole CD; Currie CJ; Marteau P; Nielsen SK
Digestion; 2009; 80(4):241-6. PubMed ID: 19828955
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
19. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M
J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
